Veterans Affairs Severely Limits Use of GlaxoSmithKline's Avandia Drug
The Department of Veterans Affairs (VA) has announced that it will now restrict the availability of GlaxoSmithKline's Avandia, a Type 2 diabetes drug.
According to the FDAnews Drug Daily Bulletin, the VA conducted its own safety review following one by the Food and Drug Administration, and concluded that Avandia, known generically as rosiglitazone, "may not afford the same margin of safety as alternative drug therapies."
Following this decision, reported the FDAnews, the VA opted to not prescribe Avandia, and only make it available for those patients who have an existing prescription for the drug.
In a New York Times article on the VA's decision, Dr. Jon LeCroy, a senior pharmaceuticals analyst, said Avandia prescriptions had declined about 60 percent.
If you or a loved one has suffered cardiac complications after ingesting Avandia, you deserve the guidance of a knowledgeable drug attorney. Get a free case review by filling out the form below.
Click To Talk To Us Online
June 2010 News
Avandia drug news about serious health risks | Weitz & Luxenberg
Avandia news, info and free lawsuit review is available for diabetes patients who suffered heart problems after taking the drug to treat Type 2 diabetes.
Senate Committee Report
Avandia Recall Prompted by Report Release | Weitz & Luxenberg Attorneys
Potential recall of diabetes drug Avandia due to risk of heart attack. Those affected can get a free lawsuit review from Weitz & Luxenberg.
News & Warnings
Avandia News and Information | Weitz & Luxenberg
Bloomberg News: FDA Warned Glaxo about Avandia Marketing in 2001